Oncopeptides AB (publ) (STO:ONCO)

Oncopeptides AB Revenue

Oncopeptides AB had revenue of 25.38M SEK in the quarter ending March 31, 2026, with 91.33% growth. This brings the company's revenue in the last twelve months to 83.24M, up 108.91% year-over-year. In the year 2025, Oncopeptides AB had annual revenue of 71.12M with 124.72% growth.

• Revenue (ttm): 83.24M
• Revenue Growth: +108.91%
• P/S Ratio: 8.41
• Revenue / Employee: 1.11M
• Employees: 75
• Market Cap: 699.66M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	71.12M	39.47M	124.72%
Dec 31, 2024	31.65M	-3.57M	-10.14%
Dec 31, 2023	35.22M	26.87M	321.54%
Dec 31, 2022	8.36M	-109.94M	-92.94%
Dec 31, 2021	118.30M	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 14, 2026

Data Sources Report a data error